Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

Clinical trial NCT06326008 · RECRUITING

Trial details

NCT number: NCT06326008
Sponsor: Beijing GoBroad Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

B-cell Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, in Relapse

Start date: 2026-03-15
Primary completion: 2026-06-15
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.